Skip to Main Content
Skip Nav Destination

New Tools to Interrogate Endocannabinoid Signalling:

From Natural Compounds to Synthetic Drugs

Drug Discovery Series


David Thurston, King's College London, UK

Series editors:

David Fox, Vulpine Science and Learning, UK

Ana Martinez, Centro de Investigaciones Biologicas-CSIC, Spain

David Rotella, Montclair State University, USA

Hong Shen, Roche Innovation Center Shanghai, China

Editorial advisor:

Ian Storer, AstraZeneca, UK

Titles in the Series:

1: Metabolism, Pharmacokinetics and Toxicity of Functional Groups

2: Emerging Drugs and Targets for Alzheimer's Disease; Volume 1

3: Emerging Drugs and Targets for Alzheimer's Disease; Volume 2

4: Accounts in Drug Discovery

5: New Frontiers in Chemical Biology

6: Animal Models for Neurodegenerative Disease

7: Neurodegeneration

8: G Protein-Coupled Receptors

9: Pharmaceutical Process Development

10: Extracellular and Intracellular Signaling

11: New Synthetic Technologies in Medicinal Chemistry

12: New Horizons in Predictive Toxicology

13: Drug Design Strategies: Quantitative Approaches

14: Neglected Diseases and Drug Discovery

15: Biomedical Imaging

16: Pharmaceutical Salts and Cocrystals

17: Polyamine Drug Discovery

18: Proteinases as Drug Targets

19: Kinase Drug Discovery

20: Drug Design Strategies: Computational Techniques and Applications

21: Designing Multi-Target Drugs

22: Nanostructured Biomaterials for Overcoming Biological Barriers

23: Physico-Chemical and Computational Approaches to Drug Discovery

24: Biomarkers for Traumatic Brain Injury

25: Drug Discovery from Natural Products

26: Anti-Inflammatory Drug Discovery

27: New Therapeutic Strategies for Type 2 Diabetes: Small Molecules

28: Drug Discovery for Psychiatric Disorders

29: Organic Chemistry of Drug Degradation

30: Computational Approaches to Nuclear Receptors

31: Traditional Chinese Medicine

32: Successful Strategies for the Discovery of Antiviral Drugs

33: Comprehensive Biomarker Discovery and Validation for Clinical Application

34: Emerging Drugs and Targets for Parkinson's Disease

35: Pain Therapeutics; Current and Future Treatment Paradigms

36: Biotherapeutics: Recent Developments using Chemical and Molecular Biology

37: Inhibitors of Molecular Chaperones as Therapeutic Agents

38: Orphan Drugs and Rare Diseases

39: Ion Channel Drug Discovery

40: Macrocycles in Drug Discovery

41: Human-based Systems for Translational Research

42: Venoms to Drugs: Venom as a Source for the Development of Human Therapeutics

43: Carbohydrates in Drug Design and Discovery

44: Drug Discovery for Schizophrenia

45: Cardiovascular and Metabolic Disease: Scientific Discoveries and New Therapies

46: Green Chemistry Strategies for Drug Discovery

47: Fragment-Based Drug Discovery

48: Epigenetics for Drug Discovery

49: New Horizons in Predictive Drug Metabolism and Pharmacokinetics

50: Privileged Scaffolds in Medicinal Chemistry: Design, Synthesis, Evaluation

51: Nanomedicines: Design, Delivery and Detection

52: Synthetic Methods in Drug Discovery: Volume 1

53: Synthetic Methods in Drug Discovery: Volume 2

54: Drug Transporters: Role and Importance in ADME and Drug Development

55: Drug Transporters: Recent Advances and Emerging Technologies

56: Allosterism in Drug Discovery

57: Anti-aging Drugs: From Basic Research to Clinical Practice

58: Antibiotic Drug Discovery: New Targets and Molecular Entities

59: Peptide-based Drug Discovery: Challenges and New Therapeutics

60: Drug Discovery for Leishmaniasis

61: Biophysical Techniques in Drug Discovery

62: Acute Brain Impairment Through Stroke: Drug Discovery and Translational Research

63: Theranostics and Image Guided Drug Delivery

64: Pharmaceutical Formulation: The Science and Technology of Dosage Forms

65: Small-molecule Transcription Factor Inhibitors in Oncology

66: Therapies for Retinal Degeneration: Targeting Common Processes

67: Kinase Drug Discovery: Modern Approaches

68: Advances in Nucleic Acid Therapeutics

69: MicroRNAs in Diseases and Disorders: Emerging Therapeutic Targets

70: Emerging Drugs and Targets for Multiple Sclerosis

71: Cytotoxic Payloads for Antibody–Drug Conjugates

72: Peptide Therapeutics: Strategy and Tactics for Chemistry, Manufacturing, and Controls

73: Anti-fibrotic Drug Discovery

74: Protein Degradation with New Chemical Modalities: Successful Strategies in Drug Discovery and Chemical Biology

75: Artificial Intelligence in Drug Discovery

76: New Tools to Interrogate Endocannabinoid Signalling: From Natural Compounds to Synthetic Drugs

How to obtain future titles on publication:

A standing order plan is available for this series. A standing order will bring delivery of each new volume immediately on publication.

For further information please contact:

Book Sales Department, Royal Society of Chemistry, Thomas Graham House, Science Park, Milton Road, Cambridge, CB4 0WF, UK

Telephone: +44 (0)1223 420066, Fax: +44 (0)1223 420247,

Visit our website at

New Tools to Interrogate Endocannabinoid Signalling:

From Natural Compounds to Synthetic Drugs

Edited by

Mauro Maccarrone

University of L'Aquila, Italy


Drug Discovery Series No. 76

Print ISBN: 978-1-78801-801-2

PDF ISBN: 978-1-83916-075-2

EPUB ISBN: 978-1-83916-085-1

Print ISSN: 2041-3203

Electronic ISSN: 2041-3211

A catalogue record for this book is available from the British Library

© The Royal Society of Chemistry 2021

All rights reserved

Apart from fair dealing for the purposes of research for non-commercial purposes or for private study, criticism or review, as permitted under the Copyright, Designs and Patents Act 1988 and the Copyright and Related Rights Regulations 2003, this publication may not be reproduced, stored or transmitted, in any form or by any means, without the prior permission in writing of The Royal Society of Chemistry or the copyright owner, or in the case of reproduction in accordance with the terms of licences issued by the Copyright Licensing Agency in the UK, or in accordance with the terms of the licences issued by the appropriate Reproduction Rights Organization outside the UK. Enquiries concerning reproduction outside the terms stated here should be sent to The Royal Society of Chemistry at the address printed on this page.

Whilst this material has been produced with all due care, The Royal Society of Chemistry cannot be held responsible or liable for its accuracy and completeness, nor for any consequences arising from any errors or the use of the information contained in this publication. The publication of advertisements does not constitute any endorsement by The Royal Society of Chemistry or Authors of any products advertised. The views and opinions advanced by contributors do not necessarily reflect those of The Royal Society of Chemistry which shall not be liable for any resulting loss or damage arising as a result of reliance upon this material.

The Royal Society of Chemistry is a charity, registered in England and Wales, Number 207890, and a company incorporated in England by Royal Charter (Registered No. RC000524), registered office: Burlington House, Piccadilly, London W1J 0BA, UK, Telephone: +44 (0) 20 7437 8656.

For further information see our web site at

Printed in the United Kingdom by CPI Group (UK) Ltd, Croydon, CR0 4YY, UK

Close Modal

or Create an Account

Close Modal
Close Modal